Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Experts Review Key Data From ESMO Congress 2021

November 29th 2021

Several leading experts discussed a variety of tumor types set to influence the next wave of investigative directions and change the standard of care for patients in abstracts at the European Society for Medical Oncology Congress 2021.

Practice-Changing and Reaffirming Data Set Up an Exciting Future in Melanoma

November 24th 2021

Positive data readouts from studies such as the phase 2/3 RELATIVITY-047 trial with relatlimab and nivolumab, and the phase 3 KEYNOTE-716 trial with pembrolizumab, cemented 2021 as a banner year for the treatment of patients with melanoma, across various stages and subtypes.

Dr. Márquez Rodas on the Preliminary Efficacy of BO-112/Pembrolizumab in Advanced Melanoma

November 23rd 2021

Iván Márquez Rodas, MD, PhD, discusses the preliminary results of the phase 2 SPOTLIGHT203 trial, which is evaluating the efficacy and safety of BO-112 plus pembrolizumab in patients with advanced melanoma.

Clinical Presentation of Basal Cell Carcinoma

November 22nd 2021

Richard Bakst, MD, and Ezra Cohen, MD, FRCPSC, FASCO, explain what the typical clinical presentation of basal cell carcinoma will look like in a patient.

Clinical Case 1 Scenario and Surgical Options for Basal Cell Carcinoma

November 22nd 2021

Kevin Emerick, MD, analyzes the data from the first clinical case scenario and touches upon potential surgical options for patients with similar diagnoses.

Dr. Nebhan on the Efficacy of Checkpoint Inhibitors in Older Patients With Cancer

November 19th 2021

Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

Patients with RCC, Melanoma Taking ICIs Can Safely Receive COVID-19 Vaccination

November 15th 2021

The COVID-19 vaccine was safe and well tolerated in patients who received immune checkpoint inhibitors for renal cell carcinoma or melanoma.

FDA Clears IND to Expand ABILITY Trial Examining MDNA11 in Solid Tumors to the United States

November 9th 2021

The FDA has greenlit an investigation new drug application to expand the ongoing phase 1/2 ABILITY trial, which is evaluating the beta-only IL-2 superagonist MDNA11 in patients with solid tumors, to clinical trial sites in the United States.

Sullivan Unpacks Breakthroughs, Challenges in the Treatment of Advanced Melanoma

November 8th 2021

The addition of immune checkpoint inhibitors and targeted therapies has paved the way for advances in the adjuvant and met-astatic setting with recent data from clinical trials demonstrating significant improvements in overall survival for patients with advanced melanoma.

New Strategies Are Needed for Patients With NRAS-Mutant Melanoma

November 3rd 2021

Although there has been dramatic progress in the treatment landscape for metastatic melanoma over the past decade, many patients whose tumors harbor NRAS mutations have not shared in the improved outcomes.

Adjuvant Pembrolizumab Maintains RFS Benefit in Resected High-Risk Stage II Melanoma

November 1st 2021

Adjuvant pembrolizumab continued to showcase improved relapse-free survival over placebo in patients with resected high-risk stage II melanoma with 6 months of additional follow-up.

Dr. Schadendorf on Expected Toxicities With Encorafenib/Binimetinib/Pembrolizumab in BRAF V600E/K-Mutated Melanoma

October 28th 2021

Dirk Schadendorf, MD, discusses expected toxicities with the combination of encorafenib, binimetinib, and pembrolizumab in BRAF V600E/K-mutated melanoma.

Cemiplimab Expands Treatment Portfolio for Patients with Basal Cell Carcinoma

October 27th 2021

Alexander J. Stratigos, MD, PhD, discussed the effect cemiplimab will have on the treatment landscape of patients with advanced BCC.

FDA Grants Fast Track Status to Cancer Vaccine UV1 for Advanced Malignant Melanoma

October 25th 2021

The FDA has granted a fast track designation to the universal cancer vaccine UV1 for use in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma, either as an add-on therapy to pembrolizumab or to ipilimumab.

ctDNA Reduction Is Potentially Predictive of OS Vs RECIST in Metastatic Uveal Melanoma

October 4th 2021

A linear correlation between magnitude of circulating tumor DNA reduction and improved overall survival was observed in patients with metastatic uveal melanoma who were treated with tebentafusp, suggesting that ctDNA may be a better surrogate end point for OS compared with RECIST response criteria.

Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA

October 1st 2021

The European Medicines Agency has validated its marketing authorization application for the fixed-dose combination of relatlimab and nivolumab in the frontline treatment of adult and pediatric patients with advanced melanoma.

Dr. Hamid on the Integration of TIL-Based Therapy Into Melanoma

September 30th 2021

Omid Hamid, MD, discusses the integration of tumor infiltrating lymphocyte–based therapy into the melanoma armamentarium.

Relatlimab/Nivolumab Improves PFS Without Added Toxicity in Metastatic Melanoma, Underscoring Frontline SOC Potential

September 30th 2021

Hussein A. Tawbi, MD, PhD, discusses the safety and efficacy achieved with relatlimab plus nivolumab in the RELATIVITY-047 trial and sheds light on the clinical significance of the data in the melanoma treatment paradigm.

FDA Grants Priority Review to Relatlimab/Nivolumab for Unresectable or Metastatic Melanoma

September 20th 2021

The FDA has granted priority review to a biologics license application for the fixed-dose combination of relatlimab plus nivolumab for the treatment of adult and pediatric patients aged 12 years and older and weighing at least 40 kg who have unresectable or metastatic melanoma.

Dr. Luke on the Results of the Phase 3 KEYNOTE-716 Trial in Melanoma

September 19th 2021

Jason J. Luke, MD, FACP, discusses the results of the phase 3 KEYNOTE-716 trial in high-risk stage II melanoma.